Verity Asset Management, Inc. Seagen Inc. Transaction History

Verity Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 22, 2023	BUY	$191.51 - $216.16 $24,704 - $27,884	129 Added 2.16%	6,090 $1.29 Billion
Q2 2023 Aug 15, 2023	BUY	$187.64 - $206.25 $6,004 - $6,600	32 Added 0.54%	5,961 $1.15 Billion
Q1 2023 May 24, 2023	SELL	$127.59 - $203.08 $18,755 - $29,852	-147 Reduced 2.42%	5,929 $1.2 Billion
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $80,750 - $95,748	688 Added 12.77%	6,076 $781 Million
Q3 2022 Nov 15, 2022	SELL	$135.27 - $180.11 $3,381 - $4,502	-25 Reduced 0.46%	5,388 $737 Million

Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $90,664 - $119,650	-758 Reduced 12.28%	5,413 $780,000
Q4 2021 Feb 08, 2022	BUY	$142.57 - $190.86 $83,260 - $111,462	584 Added 10.45%	6,171 $954,000
Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $49,715 - $59,267	349 Added 6.66%	5,587 $949,000
Q2 2021 Aug 04, 2021	BUY	$135.08 - $161.1 $58,759 - $70,078	435 Added 9.06%	5,238 $827,000
Q1 2021 May 10, 2021	BUY	$137.51 - $190.8 $170,924 - $237,164	1,243 Added 34.92%	4,803 $667,000
Q4 2020 Feb 05, 2021	BUY	$164.63 - $211.93 $586,082 - $754,470	3,560 New	3,560 $623,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Verity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Verity Asset Management, Inc. with notifications on news.